Crizotinib

Crizotinib
Clinical data
Trade names	Xalkori, others
Other names	PF-02341066; 1066
AHFS/Drugs.com	Monograph
MedlinePlus	a612018
License data	US DailyMed: Crizotinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01ED01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	43%
Protein binding	91%
Metabolism	Liver (CYP3A4/CYP3A5-mediated)
Elimination half-life	42 hours
Excretion	Faeces (63%), urine (22%)
Identifiers
	IUPAC name 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine;
CAS Number	877399-52-5 ;
PubChem CID	11626560;
IUPHAR/BPS	4903;
DrugBank	DB08700 ;
ChemSpider	9801307 ;
UNII	53AH36668S;
KEGG	D09731 ;
ChEBI	CHEBI:64310 ;
ChEMBL	ChEMBL601719 ;
PDB ligand	VGH (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID701009329 ;
ECHA InfoCard	100.166.440
Chemical and physical data
Formula	C21H22Cl2FN5O
Molar mass	450.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1(=C(C=CC(=C1[C@H](OC2=C(N=CC(=C2)C3=C[N](N=C3)C4CCNCC4)N)C)Cl)F)Cl;
	InChI InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1 ; Key:KTEIFNKAUNYNJU-GFCCVEGCSA-N ;
	(what is this?) (verify)

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.